Lopende studies klinisch studiecentrum

Abdominale heelkunde
Cardiologie
Fysische geneeskunde
Gastro-enterologie
Hematologie
Nefrologie
Neurochirurgie
Neurologie
Oncologie
Pediatrie
Pijnkliniek
Pneumologie
Psychiatrie
Reumatologie
Urologie

Abdominale heelkunde

BEET-IT: Use of beetroot juice to protect against postoperative ileus following colorectal surgery

Principal Investigator: Dr. De Keukelaere
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

AWARE: Elective adhesiolysis vs. A Wait-and-see Policy to Prevent Recurrences after Conservative Treatment of adhesive small bowel obstruction

Principal Investigator: Dr. Cornille
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

Cardiologie

SCAD: A registry of Spontaneous coronary artery dissection

Principal Investigator: Dr. Voet
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

COL BE PCI: Colchicine in Belgium in patients with coronary artery disease after percutaneous Coronary Intervention

Principal Investigator: Dr. De Boulle
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

ACO-REAL: A non-interventional study providing insights into the use of Acoramidis in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) in routine clinical practice

Principal Investigator: Dr. Goossens
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

Fysische geneeskunde

Momenteel geen studies in start-up en geen rekruterende studies.

NATIV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Principal Investigator: Prof. Dr. Schouten
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Open voor inclusie

SOPRANO: Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis

Principal Investigator: Dr. Holvoet
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

Vectors: An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Open voor inclusie

SIBERITE-1 GA45331: A phase III, multicenter, double-blind, placebo-controlled, treat-through study to assess the efficacy and safety of induction and maintenance therapy with RO7790121 in patients with moderately to severely active crohn’s disease

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Open voor inclusie

ULTRA-IBD: Understanding Local TReatment patterns and outcomes with upAdacitinib in IBD patients in Belgium

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Open voor inclusie

SKYLINE-UC: Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Principal Investigator: Dr. Holvoet
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

SYNERGY-Outcomes: A master protocol for a randomized controlled Clinical trial of multiple Pharmacologic agents in adult participants with metabolic dysfunction-associated steatotic liver disease who are at increased risk of Developing major adverse liver outcomes

Principal Investigator: Dr. Verlinden
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Aankomende studie

SUNSCAPE-1: A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis

Principal Investigator: Dr. Holvoet
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

SUNSCAPE-2: A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis

Principal Investigator: Dr. Holvoet
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Aankomende studie

STARSCAPE-1: A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Open voor inclusie

STARSCAPE-2: A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Aankomende studie

M26-266: A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Principal Investigator: Dr. Holvoet
Studiecoördinator: Anske Van Den Abbeele (anske.vandenabbeele@vitaz.be / 03 760 2043)
Status: Aankomende studie

Hematologie

LOXO-BTK-20030: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Part 2: Pirtobrutinib monotherapy in treatment-naïve patients with CLL/SLL with 17p deletions

Principal Investigator: Dr. Van Hende
Studiecoördinator: Roseline D'hooge (roseline.dhooge@vitaz.be / 03 760 2603)
Status: Aankomende studie

J2N-MC-JZNX: A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor

Principal Investigator: Dr. Van Hende
Studiecoördinator: Veerle De Corte (veerle.decorte@vitaz.be / 03 760 7629)
Status: Open voor inclusie

BIONIC: Prospective observational study on the clinical efficacy of teclistamab in patients with relapsed and refractory multiple myeloma

Principal Investigator: Dr. Vande Broek
Studiecoördinator: Veerle De Corte (veerle.decorte@vitaz.be / 03 760 7629)
Status: Open voor inclusie

BRUMIZE: Zanubrutinib in patients with Marginal Zone Lymphoma, a multicenter observational real-world ambispective study In France and Belgium

Principal Investigator: Dr. Van Hende
Studiecoördinator: Roseline D'hooge (roseline.dhooge@vitaz.be / 03 760 2603)
Status: Open voor inclusie

EpcoReal: A multi-country, prospective observational study of epcoritamab in NHL comprising two patient cohorts (3L+ [D]LBCL and 3L+ FL)

Principal Investigator: Dr. Van Hende
Studiecoördinator: Veerle De Corte (veerle.decorte@vitaz.be / 03 760 7629)
Status: Open voor inclusie

MoMMent: A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma

Principal Investigator: Dr. Vande Broek
Studiecoördinator: Roseline D'hooge (roseline.dhooge@vitaz.be / 03 760 2603)
Status: Open voor inclusie

Nefrologie

POSIBIL6: A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

Principal Investigator: Dr. De Meester
Studiecoördinator: Lise Vermeir (lise.vermeir@vitaz.be / 03 760 7535)
Status: Open voor inclusie

Neurochirurgie

SABR-MESCC: Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial

Principal Investigator: Dr. Mercier
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Aankomende studie

Neurologie

KEDRION: A Double-blind, Randomized, Multi-Center Study Investigating Efficacy and Safety of Two Different Dosages of Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: Dr. Blomme
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

REMOTE: Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies

Principal Investigator: Dr. Lamot
Studiecoördinator: Roseline D'hooge (roseline.dhooge@vitaz.be / 03 760 2603)
Status: Open voor inclusie

ROXI-CAT-I: A Multicenter, Randomized Double-blinded, Placebo-controlled Phase 3 Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-associated Thrombosis for Participants with Solid Tumors Starting Anticancer Therapy

Principal Investigator: Dr. Lybaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Veerle De Corte (veerle.decorte@vitaz.be / 03 760 7629)
Status: Aankomende studie

ROXI-CAT-II: A Multicenter, Randomized, Open-Label, Active Comparator-Controlled Phase 3 Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for the Treatment and Secondary Prevention of Symptomatic VTE in Participants with Solid and Hematologic Cancers

Principal Investigator: Dr. Lybaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Veerle De Corte (veerle.decorte@vitaz.be / 03 760 7629)
Status: Aankomende studie

GeNeo 2.0: The Added Value of Tissue or Liquid Biopsy NGS profiling in Advanced Solid Tumor Treatment Decisions

Principal Investigator: Dr. Lybaert
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Open voor inclusie

Borstkanker

ELEGANT: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study

Principal Investigator: Prof. Dr. Kruse
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

RLY-2608-102: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

Principal Investigator: Dr. Deleu
Studiecoördinator: Luna Van Hoyweghen (luna.vanhoyweghen@vitaz.be / 03 760 7627)
Status: Open voor inclusie

TucatiniBE study: Real-world efficacy of tucatinib in patients with HER2-positive advanced breast cancer in Belgium

Principal Investigator: Dr. Everaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

PIKALO-2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer

Principal Investigator: Dr. Deleu
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

REPOWER: Real-world Evaluation of Patient Outcomes and Experiences with Ribociclib Early Adopters: A Hybrid Study with Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review

Principal Investigator: Dr. Deleu
Studiecoördinatoren: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573) en Roseline D'hooge (roseline.dhooge@vitaz.be / 03 760 2603)
Status: Aankomende studie

ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Principal Investigator: Dr. Deleu
Studiecoördinator: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

Cutaan squameus celcarcinoma

Retrospectieve evaluatie van de werkzaamheid en veiligheid van Cemiplimab voor gevorderd cutaan squameus celcarcinoma binnen het Belgisch early access programma

Principal Investigator: Prof. Dr. Kruse
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

Digestieve oncologie

CODEBREAK-301: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus Investigator’s Choice Chemotherapy (FOLFOX or FOLFIRI) with or without Bevacizumab-awwb for Treatment-naïve Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation

Principal Investigator: Dr. Dedecker
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

FOLICOLOR: Following therapy response through liquid biopsy in metastatic colorectal cancer patients

Principal Investigator: Dr. Gorleer
Studiecoördinator: Caro De Weerdt (caro.deweerdt@vitaz.be / 03 821 2115)
Status: Open voor inclusie

DNET: Digestive Neuro-Endocrine Tumors Registry: An epidemiological and medical data collection of patients suffering from Digestive NeuroEndocrine Tumors via an electronic registry

Principal Investigator: Dr. Lybaert
Studiecoördinator: Caro De Weerdt (caro.deweerdt@vitaz.be / 03 821 2115)
Status: Open voor inclusie

QUALI-NET: Patient-reported outcomes in neuroendocrine neoplasms: a prospective quality of life and quality of care study within NETwerk

Principal Investigator: Dr. Lybaert
Studiecoördinator: Caro De Weerdt (caro.deweerdt@vitaz.be / 03 821 2115)
Status: Open voor inclusie

PERFORMANCE: Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer: the role of diffusion weighted magnetic resonance imaging, radiomics and liquid biopsy

Principal Investigator: Dr. Lybaert
Studiecoördinator: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Open voor inclusie

SHAPERS: Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial

Principal Investigator: Dr. Lybaert
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

SAUNA: Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients

Principal Investigator: Dr. Lybaert
Studiecoördinator: Caro De Weerdt (caro.deweerdt@vitaz.be / 03 821 2115)
Status: Open voor inclusie

COLLECT-NET: Collection of liquid biopsy samples of patients with neuroendocrine neoplasms

Principal Investigator: Dr. Lybaert
Studiecoördinator: Caro De Weerdt (caro.deweerdt@vitaz.be / 03 821 2115)
Status: Open voor inclusie

Retrospective study on outcome and toxicity of treatments for cholangiocarcinoma in Belgium with a special emphasis on Pemazyre

Principal Investigator: Dr. Lybaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

Gynaecologische tumoren

RAINFOL-03: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Principal Investigator: Dr. Lamot
Studiecoördinator: Luna Van Hoyweghen (luna.vanhoyweghen@vitaz.be / 03 760 7627)
Status: Open voor inclusie

RAINFOL-04: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Principal Investigator: Dr. Lamot
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Luna Van Hoyweghen (luna.vanhoyweghen@vitaz.be / 03 760 7627)
Status: Aankomende studie

Hoofd-hals tumoren

AVEO: Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

Principal Investigator: Dr. Lybaert
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

FORTIFI-HN01 BCA101X301: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Principal Investigator: Dr. Lybaert
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

OrigAMI-5: A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Principal Investigator: Dr. Lybaert
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

Principal Investigator: Dr. Lybaert
Studiecoördinator: Jenas Stevenheydens (jenas.stevenheydens@vitaz.be / 03 760 7624)
Status: Open voor inclusie

MIRAGE-HN: A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

Principal Investigator: Dr. Lybaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

GORTEC: A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC)

Principal Investigator: Dr. Lybaert
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

Melanomen

TeLuRide-006: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma

Principal Investigator: Dr. Deleu
Studiecoördinator: Luna Van Hoyweghen (luna.vanhoyweghen@vitaz.be / 03 760 7627)
Status: Open voor inclusie

Uro-oncologie

CORPORA: CheckpOint inhibition in advanced uRothelial carcinoma: PredictiOn of response through RNA profiling

Principal Investigator: Dr. Everaert
Studiecoördinator: Luna Van Hoyweghen (luna.vanhoyweghen@vitaz.be / 03 760 7627)
Status: Open voor inclusie

Pediatrie

Momenteel geen studies in start-up en geen rekruterende studies.

Pijnkliniek

ENDLESS: Open and closed loop Differential Target Multiplexed spinal cord stimulation in patients with persistent spinal pain syndrome type II: a European multicenter cohort study

Principal Investigator: Dr. Smet
Studiecoördinator: Tamy Bonte (tamy.bonte@vitaz.be / 03 760 2390)
Status: Open voor inclusie

ONFIELD: A monocentric, single-arm, single-blind withdrawal first-in-human study to assess the initial safety, tolerability, and effectiveness of the ONSS bilateral occipital nerve field stimulation system for the prophylactic treatment of chronic cluster headache in difficult-to-treat subjects.

Principal Investigator: Prof. Dr. Van Buyten
Studiecoördinator: Tamy Bonte (tamy.bonte@vitaz.be / 03 760 2390)
Status: Open voor inclusie

PERSIST: Post market Evaluation of real world outcomes and durability to support implantable spinal cord stimulation (SCS) therapy

Principal Investigator: Dr. Smet
Studiecoördinator: Tamy Bonte (tamy.bonte@vitaz.be / 03 760 2390)
Status: Aankomende studie

Pneumologie

PACIFIC-8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

Principal Investigator: Dr. Deschepper
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Open voor inclusie

MOMENT: Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met nOn sMall cEll caNcer regisTry)

Principal Investigator: Dr. Deschepper
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Open voor inclusie

IMMUNO-MESODEC: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma

Principal Investigator: Dr. Deschepper
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Open voor inclusie

MK2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery

Principal Investigator: Dr. Deschepper
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

M18-868: Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Principal Investigator: Dr. Deschepper
Studiecoördinator: Lany Vandenbosch (lany.vandenbosch@vitaz.be / 03 760 2602)
Status: Open voor inclusie

BNT327-06: A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

Principal Investigator: Dr. Van de Kerkhove
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

EU PAL-COPD: A stepped wedge randomised controlled trial and process evaluation of the ICLEAR-EU intervention to integrate palliative care in the treatment of people with advanced COPD and their family caregivers

Principal Investigator: Dr. Verstraeten
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

ENDURA-1: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

Principal Investigator: Dr. Yserbyt
Studiecoördinator: Tamy Bonte (tamy.bonte@vitaz.be / 03 760 2390)
Status: Open voor inclusie

CLEAR: A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

Principal Investigator: Dr. Goeminne
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Principal Investigator: Dr. Deschepper
Studiecoördinator: Lany Vandenbosch (lany.vandenbosch@vitaz.be / 03 760 2602)
Status: Aankomende studie

EVOKE-SCLC-04: A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Principal Investigator: Dr. Van de Kerkhove
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

LEPIDOPTERA: Prospective, Multi‐country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Approved Amivantamab-containing Regimens Under Standard Clinical Practice

Principal Investigator: Dr. Deschepper
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Open voor inclusie

TROPION-Lung17: A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Principal Investigator: Dr. Deschepper
Studiecoördinator: Lany Vandenbosch (lany.vandenbosch@vitaz.be / 03 760 2602)
Status: Open voor inclusie

TeLuRide-008: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer

Principal Investigator: Dr. Deschepper
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Status: Aankomende studie

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC without progression after platinum-based concurrent chemoradiation therapy

Principal Investigator: Dr. Deschepper
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Aankomende studie

AndroMETa-Lung-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan (ABBV-400) in Combination with a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Principal Investigator: Dr. Deschepper
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Lany Vandenbosch (lany.vandenbosch@vitaz.be / 03 760 2602)
Status: Aankomende studie

KANDLELIT-007: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

Principal Investigator: Dr. Deschepper
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Aankomende studie

3082-CL-5301: A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

Principal Investigator: Dr. Van de Kerkhove
Contactpersoon: Isabel De Brabander (isabel.debrabander@vitaz.be / 03 760 2573)
Studiecoördinator: Kirsten Van Camp (kirsten.vancamp@vitaz.be / 03 760 2032)
Status: Aankomende studie

Psychiatrie

Momenteel geen studies in start-up en geen rekruterende studies.

Reumatologie

Momenteel geen studies in start-up en geen rekruterende studies.

Urologie

Thunder: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Principal Investigator: Dr. De Troyer
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer (mCRPC)

Principal Investigator: Dr. Everaert
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

Moonrise-1: TAR-210 Versus Single Agent Intravesical Chemotherapy in Participants With FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC)

Principal Investigator: Dr. De Troyer
Studiecoördinator: Sophie Traen (sophie.traen@vitaz.be / 03 760 7565)
Status: Open voor inclusie

U bent hier

Lopende studies klinisch studiecentrum

Volg ons op sociale media